Ouyang Jun, Wu Deping, Gan Yumei, Tang Yuming, Wang Hui, Huang Jiangnan
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Cell Death Dis. 2025 Mar 18;16(1):183. doi: 10.1038/s41419-025-07525-z.
Cardiovascular diseases are the leading causes of death worldwide. However, there are still shortcomings in the currently employed treatment methods for these diseases. Therefore, exploring the molecular mechanisms underlying cardiovascular diseases is an important avenue for developing new treatment strategies. Previous studies have confirmed that metabolic and epigenetic alterations are often involved in cardiovascular diseases across patients. Moreover, metabolic and epigenetic factors interact with each other and affect the progression of cardiovascular diseases in a coordinated manner. Lactylation is a novel posttranslational modification (PTM) that links metabolism with epigenetics and affects disease progression. Therefore, analyzing the crosstalk between cellular metabolic and epigenetic factors in cardiovascular diseases is expected to provide insights for the development of new treatment strategies. The purpose of this review is to describe the relationship between metabolic and epigenetic factors in heart development and cardiovascular diseases such as heart failure, myocardial infarction, and atherosclerosis, with a focus on acylation and methylation, and to propose potential therapeutic measures.
Cell Death Dis. 2025-3-18
Biochim Biophys Acta Mol Basis Dis. 2024-8
Biomed Pharmacother. 2021-5
Mol Aspects Med. 2012-9-6
Trends Pharmacol Sci. 2015-3-7
Eur Rev Med Pharmacol Sci. 2014-10
Curr Diab Rep. 2015-12
MedComm (2020). 2025-9-1
Crit Rev Biochem Mol Biol. 2024-10
Cardiovasc Res. 2024-12-4
Environ Sci Technol. 2024-10-1
J Cell Mol Med. 2024-8